- Home
- FRME vs LIVN Comparison
FRME vs LIVN Comparison
Compare FRME & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- LIVN
- Stock Information
- Founded
- FRME 1893
- LIVN 1987
- Country
- FRME United States
- LIVN United Kingdom
- Employees
- FRME N/A
- LIVN N/A
- Industry
- FRME Major Banks
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- FRME Finance
- LIVN Health Care
- Exchange
- FRME Nasdaq
- LIVN Nasdaq
- Market Cap
- FRME 2.3B
- LIVN 2.1B
- IPO Year
- FRME N/A
- LIVN 1993
- Fundamental
- Price
- FRME $39.54
- LIVN $54.13
- Analyst Decision
- FRME Buy
- LIVN Strong Buy
- Analyst Count
- FRME 3
- LIVN 7
- Target Price
- FRME $46.67
- LIVN $59.29
- AVG Volume (30 Days)
- FRME 312.1K
- LIVN 820.1K
- Earning Date
- FRME 07-23-2025
- LIVN 08-06-2025
- Dividend Yield
- FRME 3.70%
- LIVN N/A
- EPS Growth
- FRME 23.41
- LIVN N/A
- EPS
- FRME 3.85
- LIVN N/A
- Revenue
- FRME $638,723,000.00
- LIVN $1,309,329,000.00
- Revenue This Year
- FRME $14.80
- LIVN $8.02
- Revenue Next Year
- FRME $4.35
- LIVN $5.83
- P/E Ratio
- FRME $10.11
- LIVN N/A
- Revenue Growth
- FRME 6.22
- LIVN 8.23
- 52 Week Low
- FRME $33.13
- LIVN $32.48
- 52 Week High
- FRME $46.13
- LIVN $57.35
- Technical
- Relative Strength Index (RSI)
- FRME 55.32
- LIVN 77.93
- Support Level
- FRME $36.75
- LIVN $41.02
- Resistance Level
- FRME $38.04
- LIVN $49.90
- Average True Range (ATR)
- FRME 0.88
- LIVN 1.50
- MACD
- FRME 0.07
- LIVN 1.17
- Stochastic Oscillator
- FRME 69.92
- LIVN 99.54
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.